Close this search box.

Lifespin Launches Commercial Access to its Metabolic Profiler Software and Database for Pharma and Biobank Services

New commercial services will provide powerful insights to aid in research, development, and manufacturing by pharmaceutical companies and biobanks.

BOSTON, MA, September 13, 2022 — Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has launched a new commercial service for the pharmaceutical and biobanking industry to assist companies in key phases of research, development, and manufacturing.

Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic drug monitoring and longitudinal treatment monitoring.

“Making our technology platform accessible to the pharma and biobanking industry will provide the opportunity for deeper clinical insights and improve stratification of patient data in clinical trials,” said Dr. Ali Tinazli, CEO of Lifespin GmbH. “The comprehensive and quantitative metabolic profiling services will enable pharmaceutical companies in particular to perform a range of precision phenotyping of cell or animal models and patient cohorts.

Leveraging Lifespin’s Comprehensive Metabolic Database

Lifespin has built one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. Leveraging this resource can offer significant benefits to researchers in the pharma and biobank fields.

“The human and financial costs of failed drug candidates or drugs being recalled after launch can be extraordinary,” Tinazli said. “Our goal is to provide the pharma and biobank scientists with yet another powerful resource in their development toolbox, including our advanced algorithms and database, to enhance their earlier phase analysis and to help better identify the strengths and weaknesses of compounds in study during research through clinical trials.”

“Our proprietary platform enables quantitative and highly reproducible metabolic profiling with minimum time and low sample volume without the need for sample preparation,” said Dr. Michael Helou, Head of Product and Business Development at Lifespin. “The highly precise, accurate and cost-effective analysis will be a powerful add-on for quality control, drug discovery as well as monitoring at any stage of drug development. The unique metabolic signature will support pharma companies to come one step closer to personalized and precision medicine treating patients related to their individual reaction to drugs.”

#            #            #


Lifespin ( is a deep data company that maps human health based on snapshots of metabolic states. Lifespin has standardized the baseline for human health to detect distinct deviations in the human metabolism caused by diseases. Studies show that pathogenesis impacts metabolism, causing specific changes in the presence and quantity of metabolites. Lifespin is building an in-house biobank that already consists of more than 200,000 human blood samples. Lifespin’s proprietary diagnostic technology platform can quantitatively capture individual metabolisms, i.e., up to hundreds of metabolite concentrations with a single Nuclear Magnetic Resonance (NMR) measurement. Utilizing its proprietary technology, Lifespin is performing quantitative in-house measurements of metabolomes, digitizing metabolic profiles that include billions of metabolic relationships. These digital metabolic profiles allow systematic mapping across various health conditions and will enable differential diagnosis and early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine. Tests for the detection of neurological, cancer, and inflammatory diseases are in the pipeline with first regulated products expected in 2023. Lifespin’s cloud-based business model is built on its proprietary Software-as-a-Service (SaaS) platform for diagnostics and health information and is globally scalable. Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and other prominent leaders in the relevant fields of study.

Caption: Partners get access to Lifespin’s proprietary software – with its scalability as Software-as-a-Service (SaaS) deep health data insights can be made available globally to participating organizations. The metabolic phenotype of an individual sample with hundreds of analytes is measured quantitatively with NMR and processed with Lifespin™ proprietary advanced artificial intelligence (AI) and deep learning algorithms for metabolic profiling and phenotyping in the context of compounds and treatment with results being delivered via the cloud (Illustration: Lifespin GmbH).

Dr. Ali Tinazli, CEO, , +1 310-467-1112 and +49-160-257-3458
David Paine, Public Relations, PaineLab,, +1 949-233-0050

More from press and media

Scroll to Top

Dr. Roland Geyer

10+ years experience in NMR-based metabolomics and diagnostic.

Dr. Renate Kirchhöfer

CDO & Co-Founder
20+ years developing NMR-applications and bringing them to regulated markets.

Dr. Fritz Huber

CEO & Co-Founder
20+ years developing and marketing NMR-based assays—he is a pioneer in this field.

Dr. Ali Tinazli

CEO, lifespin GmbH

15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP).